市場調查報告書
商品編碼
1471194
多模態成像市場:按產品、技術、應用和最終用戶分類 - 2024-2030 年全球預測Multimodal Imaging Market by Product (Multimodal Imaging Equipment, Reagents, Software), Technology (PET/CT, PET/MRI, SPECT/CT), Application, End User - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年多模態成像市場規模為28.3億美元,預計2024年將達30億美元,2030年將達43億美元,複合年成長率為6.18%。
多模態成像包括先進成像技術的開發、製造、分銷和利用,這些技術將兩種或多種顯像模式整合到單一設備或系統中。對慢性病早期診斷的日益關注、技術的進步以及患有與老齡化相關疾病的全球人口老化正在增加多模態成像的使用。然而,多模態影像系統的高昂採集費用和維護成本可能會阻礙其普及,特別是在醫療保健預算有限的新興國家。也就是說,人工智慧驅動的演算法預計將有助於簡化多種模式的資料分析,同時提高診斷準確性,同時減少處理時間。
主要市場統計 | |
---|---|
基準年[2023] | 28.3億美元 |
預測年份 [2024] | 30億美元 |
預測年份 [2030] | 43億美元 |
複合年成長率(%) | 6.18% |
產品:疾病診斷多模態影像設備的需求增加
多模態影像設備採用多種模態,例如電腦斷層掃描 (CT)、光學同調斷層掃描(OCT)、磁振造影(MRI) 和超音波正子掃描(PET),來檢測各種生物組織並拍攝結構的詳細影像。試劑透過增強體內不同組織之間的對比或突出與疾病相關的特定分子標靶,在多模態成像中發揮重要作用。多模態成像中使用的常見試劑包括用於 PET/SPECT 研究的放射性同位素、用於 MRI 研究的钆顯影劑、用於 CT 研究的碘化合物以及用於光學成像的螢光染料。多模態成像軟體解決方案能夠擷取、處理、分析和視覺化來自各種顯像模式的資料。在處理需要整合各種模態影像的複雜疾病時,多模態成像軟體至關重要。
應用:擴大多模態影像在癌症領域的應用
在循環系統領域,多模態影像為醫療專業人員提供有關心臟組織的結構、功能和灌注的詳細資訊。典型的診斷影像技術包括超音波心動圖、核心臟病學和心臟磁振造影(MRI)。臨床應用包括利用多模態影像來增強診斷、治療計劃和疾病監測的各種醫療領域。 CT(電腦斷層掃描)、MRI、PET(正子斷層掃描)和超音波等技術應用於各種臨床環境,包括整形外科、胃腸病學、婦科和小兒科。在神經學應用中,多模態成像對於透過結合結構資料和功能資訊來了解大腦功能和診斷阿茲海默症和多發性硬化症等神經系統疾病至關重要。腫瘤學多模態影像對於早期癌症檢測、監測治療反應和識別治療後復發具有重要意義。
這是技術。 PET/CT技術因其高靈敏度和特異性而成為重要的應用領域。
PET/CT(正子斷層掃描/電腦斷層掃描)是一種將 PET 的功能資訊與 CT 的解剖細節結合的影像技術。它用於腫瘤學、心臟病學和神經病學的診斷、分期和治療效果評估。此外,PET/磁振造影(PET/MRI) 是一種混合技術,它將 PET 獲得的代謝資訊與 MRI 提供的高解析度軟組織對比度相結合。這種模式可用於兒童腫瘤學、神經退化性疾病的腦部影像和心血管影像。 SPECT/CT(單光子發射電腦斷層掃描)是一種高度通用的混合成像方法,結合了功能性 SPECT資料和解剖 CT 資訊。它主要用於整形外科、心臟和腫瘤診斷成像。
最終用戶:診斷中心對多模態成像的需求不斷成長
多模態成像技術被學術和研究機構使用,因為它們需要先進的工具來更好地了解各種生物過程。多模態成像使研究人員能夠利用高解析度影像研究複雜的細胞結構、分子相互作用和疾病病理學。診斷中心提供重要的診斷服務,如放射學、超音波、磁振造影(MRI)、電腦斷層掃描(CT)、核子醫學(NM)、光學同調斷層掃描(OCT)和正子斷層掃描(PET)掃描。慢性病的增加和人口老化增加了醫院環境對先進影像處理系統的需求。
區域洞察
在美國和加拿大,人口老化和慢性病的迅速增加正在增加對先進診斷工具的需求。對研發的投資已產生大量專利申請,展示了該領域的創新。隨著學術、臨床和產業相關人員促進創新,歐盟 (EU) 國家的多模態成像市場也不斷成長。在中東和非洲地區,醫療基礎設施的改善正在為多模態成像市場創造巨大的成長機會。各國政府正在投資醫療保健,以應對癌症和心血管疾病等非傳染性疾病的增加,其中先進影像技術發揮關鍵作用。由於快速都市化、醫療設施擴張和可支配收入增加等因素,中國、日本、印度和其他亞太國家的多模態成像市場正在穩步擴張。
FPNV定位矩陣
FPNV定位矩陣對於評估多模態影像市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標,以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估,供應商被分為四個成功程度不同的像限。最前線 (F)、探路者 (P)、利基 (N) 和重要 (V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對多模態成像市場中供應商的現狀進行深入而詳細的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻,以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外,該分析還提供了對該細分市場競爭特徵的寶貴見解,包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略,從而在市場上獲得競爭優勢。
1. 市場滲透率:提供有關主要企業所服務的市場的全面資訊。
2. 市場開拓:我們深入研究利潤豐厚的新興市場,並分析其在成熟細分市場的滲透率。
3. 市場多元化:包括新產品發布、開拓地區、最新發展和投資的詳細資訊。
4. 競爭評估和情報:對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。
5. 產品開發與創新:包括對未來技術、研發活動以及突破性產品開發的見解。
1.多模態成像市場的市場規模和預測是多少?
2.在多模態影像市場的預測期內,我們應該考慮投資哪些產品和應用?
3.多模態成像市場的技術趨勢和法規結構是什麼?
4.多模態成像市場主要廠商的市場佔有率為何?
5. 進入多模態影像市場的合適模式和策略手段是什麼?
[187 Pages Report] The Multimodal Imaging Market size was estimated at USD 2.83 billion in 2023 and expected to reach USD 3.00 billion in 2024, at a CAGR 6.18% to reach USD 4.30 billion by 2030.
Multimodal imaging encompasses developing, producing, distributing, and utilizing advanced imaging technologies that combine two or more imaging modalities within a single device or system.The rising focus on early diagnosis of chronic diseases, technological advancements, an aging global population with age-related ailments increases the use of multimodal imaging. However, multimodal imaging systems' high acquisition and maintenance costs may hinder widespread adoption, especially in emerging economies with limited healthcare budgets. Nevertheless, AI-powered algorithms are expected to help streamline data analysis from multiple modalities simultaneously improving diagnostic accuracy while reducing processing time.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 2.83 billion |
Estimated Year [2024] | USD 3.00 billion |
Forecast Year [2030] | USD 4.30 billion |
CAGR (%) | 6.18% |
Product: Increasing demand for multimodal imaging equipments for disease diagnostics
Multimodal imaging equipment employs multiple modalities such as computed tomography (CT), optical coherence tomography (OCT), magnetic resonance imaging (MRI), ultrasound positron emission tomography (PET) to capture detailed images of various biological tissues and structures. Reagents play a crucial role in multimodal imaging by enhancing the contrast between different tissues in the body or highlighting specific molecular targets related to diseases. Some common reagents used in multimodal imaging are radioisotopes for PET/Single photon emission computed tomography (SPECT) scans, gadolinium-based contrast agents for MRI, iodinated compounds for CT scans, and fluorescent dyes for optical imaging. Software solutions in multimodal imaging enable the acquisition, processing, analysis, and visualization of data from different imaging modalities. Multimodal imaging software is essential when dealing with complex diseases requiring the integration of images from various modalities.
Application: Expanding use of multimodal imaging for oncology
In cardiology applications, multimodal imaging provides healthcare professionals with detailed information regarding cardiac tissue structure, function, and perfusion. Some prominent imaging techniques include echocardiography, nuclear cardiology, and cardiac magnetic resonance imaging (MRI). Clinical applications encompass various medical disciplines that utilize multimodal imaging to enhance diagnosis, treatment planning, and disease monitoring. Techniques such as computed tomography (CT), MRI, positron emission tomography (PET), and ultrasound are employed in diverse clinical settings, including orthopedics, gastroenterology, gynecology, and pediatrics. In neurology applications, multimodal imaging is vital in understanding brain function and diagnosing neurological disorders such as Alzheimer's or multiple sclerosis by combining structural data with functional information. Oncologic multimodal imaging has significance in early detection of cancer, monitoring treatment response, and identifying recurrence post-therapy
Technology: Significant applications of PET/CT technology owing to its high sensitivity and specificity
Positron Emission Tomography/Computed Tomography (PET/CT) is an imaging technique that combines the functional information from PET with the anatomical details of CT. It is utilized in oncology, cardiology, and neurology applications for diagnosis, staging, and assessment of treatment response. Moreover, PET/Magnetic Resonance Imaging (PET/MRI) is a hybrid technology combining the metabolic information obtained from PET with the high-resolution soft tissue contrast provided by MRI. This modality benefits pediatric oncology, brain imaging for neurodegenerative diseases, and cardiovascular imaging. Single Photon Emission Computed Tomography/Computed Tomography (SPECT/CT) is a versatile hybrid imaging modality that combines functional SPECT data with anatomical CT information. It is primarily employed in orthopedic, cardiac, and oncological imaging.
End-User: Proliferating demand for multimodal imaging in diagnostic centers
Academic and research institutes use multimodal imaging technology as they need advanced tools to offer better insights into various biological processes. It enables researchers to study intricate cellular structures, molecular interactions, and disease pathology with high-resolution images. Diagnostic centers provide crucial diagnostic services, including radiology, ultrasound, magnetic resonance imaging (MRI), computed tomography (CT), nuclear medicine (NM), optical coherence tomography (OCT), and positron emission tomography (PET) scans. The increased chronic illness and the growing geriatric population have raised the need for advanced imaging systems in hospital settings.
Regional Insights
In the United States and Canada, there has been a rising demand for advanced diagnostic tools due to an aging population and surge in prevalence of chronic diseases. Investments in research and development have led to numerous patents being filed, showcasing innovation in this sector. European Union countries have also seen growth in the multimodal imaging market with increasing collaboration between academia, clinical institutions, and industry players driving innovation. In the Middle East and Africa region, improving healthcare infrastructure has created a significant growth opportunities multimodal imaging market. Governments are investing in healthcare to address the rising incidences of non-communicable diseases such as cancer and cardiovascular disorders where advanced imaging plays a crucial role. China, Japan, India, and other Asia Pacific countries are experiencing robust expansion of their multimodal imaging markets due to factors such as rapid urbanization, expanding healthcare facilities, and increasing disposable income.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Multimodal Imaging Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Multimodal Imaging Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Multimodal Imaging Market, highlighting leading vendors and their innovative profiles. These include Bruker Corporation, Canon Inc., GE Healthcare, Infraredx Inc., International Business Machines Corporation, Koninklijke Philips N.V., Mediso Ltd., MR Solutions Ltd., Neusoft Medical Systems Co., Ltd., Northridge Tri-Modality Imaging, Inc., PerkinElmer, Inc., Shanghai United Imaging Healthcare Co., Ltd., Siemens AG, Spectrum Dynamics Medical, Inc., and Topcon Corporation.
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Multimodal Imaging Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Multimodal Imaging Market?
3. What are the technology trends and regulatory frameworks in the Multimodal Imaging Market?
4. What is the market share of the leading vendors in the Multimodal Imaging Market?
5. Which modes and strategic moves are suitable for entering the Multimodal Imaging Market?